|
|
|
|
HB4587 Enrolled |
|
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| AN ACT concerning public health.
|
| 2 |
| Be it enacted by the People of the State of Illinois,
|
| 3 |
| represented in the General Assembly:
|
| 4 |
| Section 1. Short title. This Act may be cited as the Lupus |
| 5 |
| Education and Awareness Act. |
| 6 |
| Section 5. Legislative findings and purpose. |
| 7 |
| (a) The General Assembly finds the following: |
| 8 |
| (1) Lupus is an urgent national health issue. Lupus is |
| 9 |
| the result of an immune system that is unbalanced and can |
| 10 |
| become destructive to any organ or tissue in the body. |
| 11 |
| Lupus is unpredictable and potentially fatal, yet no |
| 12 |
| satisfactory treatment exists. Its health consequences |
| 13 |
| include heart attacks, strokes, seizures, and organ |
| 14 |
| failure. |
| 15 |
| (2) National data indicates that more than 1.5 million |
| 16 |
| Americans live with some form of lupus; lupus affects women |
| 17 |
| 9 times more often than men, and 80% of newly diagnosed |
| 18 |
| cases of lupus develop among women of childbearing age. An |
| 19 |
| estimated 65,000 people with lupus reside in Illinois. |
| 20 |
| (3) Lupus disproportionately affects women of color; |
| 21 |
| it is 2 to 3 times more common among African Americans, |
| 22 |
| Hispanics and Latinos, Asians, and Native Americans and is |
| 23 |
| generally more prevalent in minority populations, a health |
|
|
|
HB4587 Enrolled |
- 2 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| disparity that remains unexplained. |
| 2 |
| (4) No new drugs have been approved by the U.S. Food |
| 3 |
| and Drug Administration specifically for lupus in 50 years |
| 4 |
| and, while current treatments for the disease can be |
| 5 |
| effective, they can lead to damaging side effects. |
| 6 |
| (5) The pain and fatigue associated with lupus can |
| 7 |
| threaten one's ability to live independently, make it |
| 8 |
| difficult to maintain employment, and lead normal lives. |
| 9 |
| One in 5 people with lupus is disabled by the disease and |
| 10 |
| consequently receives support from government programs, |
| 11 |
| including Medicare, Medicaid, Social Security Disability, |
| 12 |
| and Social Security Supplemental Income. |
| 13 |
| (6) The estimated average annual total of direct and |
| 14 |
| indirect costs for an individual with lupus is $21,000; for |
| 15 |
| people who have the most serious form of lupus, medical |
| 16 |
| costs can greatly exceed this amount, causing a significant |
| 17 |
| economic, emotional, and social burden to the entire family |
| 18 |
| and society. |
| 19 |
| (b) The purpose of this Act is to create a multi-pronged, |
| 20 |
| statewide program to promote public and health professional |
| 21 |
| awareness among State and local health and human services |
| 22 |
| officials, physicians, nurses, and other health care providers |
| 23 |
| and increase knowledge concerning the causes and consequences |
| 24 |
| of lupus, the importance of early diagnosis and appropriate |
| 25 |
| management, and effective treatment and management strategies |
| 26 |
| by taking the following actions: |
|
|
|
HB4587 Enrolled |
- 3 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| (1) Conducting educational and training programs for |
| 2 |
| health professionals on lupus diagnosis and management.
|
| 3 |
| (2) Disseminating medically sound educational |
| 4 |
| materials and information on lupus research findings to |
| 5 |
| patients and health care professionals.
|
| 6 |
| (3) Fostering greater public understanding and |
| 7 |
| awareness of lupus statewide.
|
| 8 |
| Section 10. Definitions. For the purpose of this Act: |
| 9 |
| "Department" means the Department of Public Health. |
| 10 |
| "Director" means the Director of Public Health. |
| 11 |
| "Panel" means the Interagency and Partnership Advisory |
| 12 |
| Panel on Lupus. |
| 13 |
| "Program" means the Lupus Education and Awareness Program |
| 14 |
| (LEAP).
|
| 15 |
| Section 15. Establishment of the Lupus Education and |
| 16 |
| Awareness Program.
|
| 17 |
| (a) Subject to appropriation, there is created within the |
| 18 |
| Department of Public Health the Lupus Education and Awareness |
| 19 |
| Program (LEAP). The Program shall be composed of various |
| 20 |
| components, including, but not limited to, public awareness |
| 21 |
| activities and professional education programs. Subject to |
| 22 |
| appropriation, the Interagency and Partnership Advisory Panel |
| 23 |
| on Lupus is created to oversee LEAP and advise the Department |
| 24 |
| in implementing LEAP. |
|
|
|
HB4587 Enrolled |
- 4 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| (b) The Department shall establish, promote, and maintain |
| 2 |
| the Lupus Education and Awareness Program with an emphasis on |
| 3 |
| minority populations and at-risk communities in order to raise |
| 4 |
| public awareness, educate consumers, and educate and train |
| 5 |
| health professionals, human service providers, and other |
| 6 |
| audiences. |
| 7 |
| The Department shall work with a national organization that |
| 8 |
| deals with lupus to implement programs to raise public |
| 9 |
| awareness about the symptoms and nature of lupus, personal risk |
| 10 |
| factors, and options for diagnosing and treating the disease, |
| 11 |
| with a particular focus on populations at elevated risk for |
| 12 |
| lupus, including women and communities of color. |
| 13 |
| The Program shall include initiatives to educate and train |
| 14 |
| physicians, health care professionals, and other service |
| 15 |
| providers on the most up-to-date and accurate scientific and |
| 16 |
| medical information regarding lupus diagnosis, treatment, |
| 17 |
| risks and benefits of medications, research advances, and |
| 18 |
| therapeutic decision making, including medical best practices |
| 19 |
| for detecting and treating the disease in special populations. |
| 20 |
| These activities shall include, but not be limited to, all of |
| 21 |
| the following: |
| 22 |
| (1) Distribution of medically-sound health information |
| 23 |
| produced by a national organization that deals with lupus |
| 24 |
| and government agencies, including, but not limited to, the |
| 25 |
| National Institutes of Health, the Centers for Disease |
| 26 |
| Control and Prevention, and the Social Security |
|
|
|
HB4587 Enrolled |
- 5 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| Administration, through local health departments, schools, |
| 2 |
| agencies on aging, employer wellness programs, physicians |
| 3 |
| and other health professionals, hospitals, health plans |
| 4 |
| and health maintenance organizations, women's health |
| 5 |
| programs, and nonprofit and community-based organizations. |
| 6 |
| (2) Development of educational materials for health |
| 7 |
| professionals that identify the latest scientific and |
| 8 |
| medical information and clinical applications. |
| 9 |
| (3) Working to increase knowledge among physicians, |
| 10 |
| nurses, and health and human services professionals about |
| 11 |
| the importance of lupus diagnosis, treatment, and |
| 12 |
| rehabilitation.
|
| 13 |
| (4) Support of continuing medical education programs |
| 14 |
| presented by the leading State academic institutions by |
| 15 |
| providing them with the most up-to-date information.
|
| 16 |
| (5) Providing statewide workshops and seminars for |
| 17 |
| in-depth professional development regarding the care and |
| 18 |
| management of patients with lupus in order to bring the |
| 19 |
| latest information on clinical advances to care providers.
|
| 20 |
| (6) Development and maintenance of a directory of |
| 21 |
| lupus-related services and lupus health care providers |
| 22 |
| with specialization in services to diagnose and treat |
| 23 |
| lupus. The Department shall disseminate this directory to |
| 24 |
| all stakeholders, including, but not limited to, |
| 25 |
| individuals with lupus, families, and representatives from |
| 26 |
| voluntary organizations, health care professionals, health |
|
|
|
HB4587 Enrolled |
- 6 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| plans, and State and local health agencies. |
| 2 |
| (c) The Director shall do all of the following: |
| 3 |
| (1) Designate a person in the Department to oversee the |
| 4 |
| Program.
|
| 5 |
| (2) Identify the appropriate entities to carry out the |
| 6 |
| Program, including, but not limited to, the following: |
| 7 |
| local health departments, schools, agencies on aging, |
| 8 |
| employer wellness programs, physicians and other health |
| 9 |
| professionals, hospitals, health plans and health |
| 10 |
| maintenance organizations, women's health organizations, |
| 11 |
| and nonprofit and community-based organizations.
|
| 12 |
| (3) Base the Program on the most current scientific |
| 13 |
| information and findings.
|
| 14 |
| (4) Work with governmental entities, community and |
| 15 |
| business leaders, community organizations, health care and |
| 16 |
| human service providers, and national, State, and local |
| 17 |
| organizations to coordinate efforts to maximize State |
| 18 |
| resources in the areas of lupus education and awareness.
|
| 19 |
| (5) Use public health institutions for dissemination |
| 20 |
| of medically sound health materials.
|
| 21 |
| (d) The Department shall establish and coordinate the |
| 22 |
| Interagency and Partnership Advisory Panel on Lupus consisting |
| 23 |
| of 15 members, one of whom shall be appointed by the Director |
| 24 |
| as the chair.
The Panel shall be composed of: |
| 25 |
| (1) at least 3 individuals with lupus;
|
| 26 |
| (2) three representatives from relevant State agencies |
|
|
|
HB4587 Enrolled |
- 7 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| including the Department;
|
| 2 |
| (3) three scientists with experience in lupus who |
| 3 |
| participate in various fields of scientific endeavor, |
| 4 |
| including, but not limited to, biomedical research, |
| 5 |
| social, translational, behavioral, and epidemiological |
| 6 |
| research, and public health;
|
| 7 |
| (4) two medical clinicians with experience in treating |
| 8 |
| people with lupus; and
|
| 9 |
| (5) four representatives from relevant nonprofit |
| 10 |
| women's and health organizations, including one |
| 11 |
| representative from a national organization that deals |
| 12 |
| with the treatment of lupus. |
| 13 |
| Individuals and organizations may submit nominations to |
| 14 |
| the Director to be named to the Panel. Such nominations may |
| 15 |
| include the following: |
| 16 |
| (i) representatives from appropriate State departments |
| 17 |
| and agencies, such as entities with responsibility for |
| 18 |
| health disparities, public health programs, education, |
| 19 |
| public welfare, and women's health programs; |
| 20 |
| (ii) health and medical professionals with expertise |
| 21 |
| in lupus; and |
| 22 |
| (iii) individuals with lupus, and recognized experts |
| 23 |
| in the provision of health services to women, lupus |
| 24 |
| research, or health disparities. |
| 25 |
| All members of the panel shall serve terms of 2 years. A |
| 26 |
| member may be appointed to serve not more than 2 terms, whether |
|
|
|
HB4587 Enrolled |
- 8 - |
LRB096 13256 RPM 27918 b |
|
|
| 1 |
| or not consecutive.
A majority of the members of the panel |
| 2 |
| shall constitute a quorum. A majority vote of a quorum shall be |
| 3 |
| required for any official action of the Panel.
The Panel shall |
| 4 |
| meet at the call of the chair, but not less than 2 times per |
| 5 |
| year. All members shall serve without compensation, but shall |
| 6 |
| be entitled to actual, necessary expenses incurred in the |
| 7 |
| performance of their business as members of the Panel in |
| 8 |
| accordance with the reimbursement polices for the State. |
| 9 |
| Section 20. Funding. Subject to the availability of funds, |
| 10 |
| the Department may make expenditures of up to $2,500 for fiscal |
| 11 |
| year 2010 for use toward providing educational materials to |
| 12 |
| clinics serving a high percentage of minorities in this State. |
| 13 |
| The Director may accept grants, services, and property from the |
| 14 |
| federal government, foundations, organizations, medical |
| 15 |
| schools, and other entities as may be available for the |
| 16 |
| purposes of fulfilling the obligations of this Program. Any |
| 17 |
| such funds shall only supplement any appropriations made for |
| 18 |
| the implementation of this Act. The Director shall seek any |
| 19 |
| federal waiver or waivers that may be necessary to maximize |
| 20 |
| funds from the federal government to implement the Program. |
| 21 |
| Section 25. Staffing. The Department of Public Health shall |
| 22 |
| provide staffing and administrative support for the |
| 23 |
| implementation of the provisions of this Act.
|